Cargando…
Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity
[Image: see text] Combining chemotherapeutics is a promising method of improving cancer treatment; however, the clinical success of combination therapy is limited by the distinct pharmacokinetics of combined drugs, which leads to nonuniform distribution. In this study, we report a new robust approac...
Autores principales: | Liu, Yarong, Fang, Jinxu, Kim, Yu-Jeong, Wong, Michael K., Wang, Pin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018157/ https://www.ncbi.nlm.nih.gov/pubmed/24673622 http://dx.doi.org/10.1021/mp5000373 |
Ejemplares similares
-
Codelivery of Chemotherapeutics via Crosslinked Multilamellar Liposomal Vesicles to Overcome Multidrug Resistance in Tumor
por: Liu, Yarong, et al.
Publicado: (2014) -
Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
por: Zhang, Xiaoyang, et al.
Publicado: (2017) -
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
por: Li, Ke, et al.
Publicado: (2019) -
Nucleus-selective codelivery of proteins and drugs for synergistic antitumor therapy
por: Yang, Lan, et al.
Publicado: (2022) -
Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
por: Zhang, Yue, et al.
Publicado: (2017)